Merck to slash more than 100 R&D jobs from French site

Merck
Merck is shuttering an R&D site in Riom in the heart of France. (Merck)

While Merck announced it was spending a few hundred million on an early-stage biotech this morning, we have now learned that it is also shuttering an R&D site in Riom in the heart of France.

The U.S. Big Pharma is shutting down the research and manufacturing site, which has seen its use lessen over the years. It has a focus on antibiotics, anti-inflammatory and vaccine work.   

“The number of toxicology studies entrusted to the research center has considerably decreased in recent years,” according to a report by French newspaper La Montagne and later confirmed to FierceBiotech, “whose volume no longer makes it possible to ensure optimal use of the center’s capacity.”

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The research center currently has 106 employees who will be let go, with another 100 going from its manufacturing side. Merck added that it may look to sell the site off.

Read more on

Suggested Articles

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.